CMS

CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds
Endpoints
Tue, 01/3/23 - 10:22 pm
CMS
Medicare
Medicare Part B
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Endpoints
Wed, 12/21/22 - 11:31 am
Biogen
FDA
Alzheimer's disease
CMS
clinical trials
US govt addressing Medicare payments for biosimilars
Pharma Letter
Tue, 10/4/22 - 10:35 am
HHS
Medicare
biosimilars
Medicare Part B
Inflation Reduction Act
CMS
Stryker Is Smart to Pursue This Type of Reimbursement
Medical Devices and Diagnostics Industry
Wed, 05/18/22 - 10:30 am
Medtech
devices
reimbursement
Skryker
InSpace balloon implants
outpatient hospitals
CMS
Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision
Biopharma Reporter
Mon, 05/16/22 - 10:48 am
Biogen
Aduhelm
monoclonal antibodies
CMS
Alzheimer's disease
neurologists
Is Biogen Planning to Appeal CMS Aduhelm Reimbursement Decision?
BioSpace
Mon, 05/2/22 - 06:08 pm
Biogen
CMS
Alzheimer's disease
Aduhelm
The next battle in the never-ending war over Aduhelm
Stat
Fri, 04/15/22 - 01:50 pm
Biogen
Aduhelm
Medicare
CMS
Eli Lilly
Alzheimer's disease
CMS official on Alzheimer's drug coverage decision: Don't read between the lines for other accelerated approvals
Endpoints
Wed, 04/13/22 - 10:54 am
CMS
Medicare
Biogen
Aduhelm
accelerated approvals
How CMS independence is at the forefront of its Alzheimer's drug coverage decision
Endpoints
Mon, 04/11/22 - 10:34 am
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
CMS finalizes restrictions on Biogen's Alzheimer's drug coverage, will only fund use in clinical trials
Endpoints
Thu, 04/7/22 - 06:13 pm
Biogen
Aduhelm
CMS
Alzheimer's disease
clinical trials
Medicare
More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
Endpoints
Sat, 04/2/22 - 11:46 am
biosimilars
Medicare
CMS
Medicare Part D
Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
Endpoints
Mon, 02/14/22 - 11:06 am
Eli Lilly
Roche
Biogen
Alzheimer's disease
Aduhelm
CMS
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials
Endpoints
Wed, 02/9/22 - 10:53 pm
Biogen
Aduhelm
CMS
Alzheimer's disease
CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say
Fierce Pharma
Tue, 02/1/22 - 10:50 am
CMS
Biogen
Aduhelm
Eli Lilly
Roche
Alzheimer's disease
Scott Gottlieb criticizes CMS in feud over Aduhelm coverage, calls out their lack of expertise
Endpoints
Thu, 01/27/22 - 11:41 pm
Biogen
Aduhelm
CMS
Scott Gottlieb
With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment
Stat
Fri, 01/14/22 - 10:56 am
Medicare
Aduhelm
Biogen
CMS
racial disparity
Alzheimer's disease
Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years
Endpoints
Thu, 01/13/22 - 10:26 pm
Biogen
Aduhelm
CMS
drug reps
Medicare
Alzheimer's disease
For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst
Fierce Pharma
Wed, 01/12/22 - 11:01 am
CMS
Biogen
Aduhelm
Medicare
clinical trials
Alzheimer's disease
Medicare proposes to limit coverage of Biogen Alzheimer's drug
BioPharma Dive
Tue, 01/11/22 - 10:22 pm
Biogen
Aduhelm
CMS
Medicare

Pages